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Abstract
We consider the multiscale model for glioma growth introduced in [19] and extend it to account
for therapy effects. Thereby, three treatment strategies involving surgical resection, radio-, and
chemotherapy are compared for their efficiency. The chemotherapy relies on inhibiting the binding
of cell surface receptors to the surrounding tissue, which impairs both migration and proliferation.
1 Introduction
Malignant gliomas are highly invasive and heterogeneous primary brain tumors. Their treatment
is still elusive, in spite of the development and diversification of the therapeutic approaches [48].
The differentiated response of tumor cell subpopulations to treatment and the infiltrative growth
throughout the brain tissue [23, 37, 39] are two main causes for the lack of surgical, radio- and
chemotherapeutical cure. Indeed, it is largely accepted that cells with a highly proliferating phenotype
are more sensitive to both chemo and radiotherapy, whereas the migratory phenotype is attended by
reduced treatment sensitivity, see e.g., [39, 42, 60] and the references therein. Moreover, because of
the high affinity of glioma cells to myelinated fiber tracts in the white matter [24, 26], in more than
90% of cases, the recurrent tumor develops immediately adjacent to the resection margin or within
several centimeters of the resection cavity [23, 39].
In this work we address both the modeling of (infiltrative) glioma spread and growth, and the response
to surgical resection and radiotherapy. Concerning the treatment we use the idea of reducing tumor
cell migration by inhibiting the binding of cell surface receptors to the tissue fibers in the peritumoral
region (see e.g., [11, 23] and the references therein), hence also rendering the cancer cells more sensitive
against radiotherapy, in view of the go-or-grow hypothesis stating that the tumor cells can either
migrate or proliferate [9, 25, 23, 29]. On the other hand, however, the receptor binding inhibition
can also impair cell proliferation, as the latter is known to be influenced by cell-matrix (and cell-cell)
adhesion [14, 27, 32, 40, 45, 63]; hence, the balance between increasing proliferation through stopping
migration and reducing mitotic activity through inhibiting adhesion will be the driving factor for
enhancing radiosensitivity. Mathematical models for the therapy of glioma have also been considered
in [2, 51, 52], however in a much simplified monoscale case not able to account for the highly infiltrative
behavior of this type of cancer. Here we start from the multiscale setting introduced in [19] to describe
the evolution of a heterogeneous tumor consisting of migrating and proliferating glioma cells moving
along white matter tracts of white matter. The anisotropic structure of the brain is assessed from
diffusion tensor imaging (DTI) data and the model involves on the microscopic, subcellular scale the
receptor binding dynamics to the tissue fibers, while the individual cell dynamics are modeled on the
mesoscale via kinetic transport equations. A parabolic scaling allows to deduce effective equations
for the tumor growth on the macroscopic (population) scale, carrying the information from the lower
scales. This model permits to account for the infiltrative behavior of glioma and in this work we extend
it to also consider therapy in the sense stated above. Another multiscale model involving intracellular
(microscale) and extracellular pH dynamics along with the evolution of tumor cells and normal tissue
(macroscale) has been proposed in [61] and extended in [44] to include the issue of treatment with
sensitization against radiotherapy via alkalinization of the tumor microenvironment and depletion of
cancer cells via chemotherapy and radiotherapy.
This paper is organized as follows: In Section 2 we present the mathematical model and describe
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the way in which therapy is considered and implemented, then use a parabolic scaling to re-deduce
(with the changes due to modeling therapy) the effective equations for glioma spread involving the
DTI information for the patient specific brain structure and encompassing the subcellular receptor
binding dynamics in the diffusion, transport and haptotaxis coefficients. The well posedness of both
formulations (multiscale and population level, respectively) is addressed as well. Section 3 is concerned
with the assessment of the functions and parameters employed in the model, and Section 4 presents
the numerical method and the simulations obtained from our setting. Eventually, Section 5 offers
some comments about the potential of this modeling approach and further issues to be addressed in
this context.
2 Mathematical modeling
2.1 Equations on the mesoscopic and microscopic levels
In [19] we considered a model for glioma invasion relying on the go-or-grow hypothesis. In this work
we extend that setting in order to account for therapy. Thereby, in view of the migratory/proliferative
phenotype of cancer cells significantly influencing the response of tumors to various treatments like
radiotherapy and chemotherapy, we will characterize this differentiated response by considering two
tumor subpopulations: proliferative (hence non-motile) and migrating cells, respectively.
We consider the density function p(t,x,v, y) of moving cells at time t and position x ∈ Rn, with veloc-
ity v ∈ V ⊂ Rn and receptor state y ∈ R+, and the density function r(t,x, y) of resting cells. Thereby,
the receptor state y is a subcellular scale (microscale) variable and refers to the volume fraction of cell
surface receptors bound to insoluble ligands in the surrounding tissue. While it is clear that integrins
(a family of heterodimeric cell adhesion molecules playing a crucial role in cell-cell and cell-matrix
interaction [32, 33, 45]) and their binding to the ECM are essential for glioma migration [15, 63] and
it has been found that glioma cells follow the anisotropic brain structure along the white matter tracts
[24, 26], the mechanism of adhesion to the myelinated axons is still not elucidated, but integrins do not
seem to be responsible for such bindings [24]. In the following we will use the syntagma ’cell surface
receptors’ for all kinds of receptors involved in cell-tissue adhesion and will concentrate on integrins
when referring to chemotherapeutical agents which aim at inhibiting migration and proliferation. For
further discussions on the issue of glioma-tissue adhesion we refer to [17, 19].
The two cancer cell densities of interest satisfy on the mesoscale the system of partial integro-
differential equations
∂tp+∇x · (vp) + ∂y (G(y,Q, dc, dr)p)
= L[λ(y)]p− a(x, dc)p+ b(x, dc)q(vˆ)
ω
r − (l1(N) +R1(α1, dr))p, (1)
∂tr = a(x, dc)
∫
V
p(v)dv − b(x, dc)r + g(N, dc)r − (l2(N) +R2(α2, dr))r, (2)
where L[λ(y)]p := −λ(y)p+λ(y) ∫
V
K(x,v)p(v′)dv′ is the turning operator modeling the cell velocity
innovations due to contact guidance, environmental cues etc. Here the turning kernel K accounting
for such influences is taken for simplicity to be of the form (see [30]) K(x,v) := q(vˆ)ω , where vˆ is
the normalized velocity, q(x, vˆ) is the directional distribution of tissue fibers, and ω =
∫
V
q(vˆ)dv is a
scaling constant (we assume V = sSn−1, with s given) such that K is indeed a kernel. The function
λ(y) denotes as in [17, 19, 18] the turning rate of the cells. Motivated by existing experimental
evidence (see e.g., [46]) that integrins expressed by resting cells cannot in general bind their ligands,
we assume this also for our model, as we did in [19]. 1
In (1) and (4) below Q(t,x) denotes the (macroscopic) volume fraction of tissue (including as in [17, 19]
ECM and neuron bundles). The functions a(x, dc) and b(x, dc) denote the rates with which cells stop
and proliferate, respectively start moving after a resting (proliferating) phase. The cells which exit
proliferation and become motile are doing this by interacting with the tissue, which motivates the
factor q(vˆ)ω in the corresponding term of (1). Both a and b can depend on the position x and are
supposed to also depend on the dose dc of the chemotherapeutic agent. g(N, dc) and li(N) (i = 1, 2)
are functions representing gain and loss due to cell proliferation and death, respectively. Thereby, the
1In particular, this justifies the omission of the ’transport’ term w.r.t. y on the left hand side of (2)
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gain is impaired by the effect of chemotherapy and the loss is amplified by radiotherapy. The effects
of the latter are described by the terms Rj(αj , dr), where
Rj(αj , dr) =
ν∑
i=1
(1− S(αj , dr))ηδ(t− ti), ti ∈ radiotherapy (3)
with j = 1, 2, 3 and ’radiotherapy’ denoting the set of times at which ionizing radiation is applied to
the patient (with dose dr). Here ν is the number of fractions, ηδ is a C∞0 function with unit mass and
support in (−δ, δ), δ << 1 and S(αj , dr) = exp(−αjdr − βjd2r) models the survival fraction of each
subpopulation p, r or normal tissue (for j = 3), respectively, after application of radiotherapy with a
dose dr (in Gy). Thus, we adopted the linear quadratic (LQ) model [21, 28, 54], which in spite of its
shortcomings [10, 35, 65] is still the standard choice in radiation treatments (see e.g., [50, 59]). The
parameter αj represents lethal lesions produced by a single radiation track (they are linearly related to
the dose: αjdr, cell kill per Gy), while βj characterizes lethal lesions produced by two radiation tracks
(quadratically related to the dose: βjd2r, cell kill per Gy2). The relevant parameter in the LQ model is
actually the radiation sensitivity αjβj , which correlates to the cell cycle length: late responding tissues
with a slow cell cycle have a small αjβj ratio, while it is large for early responding, highly aggressive
cancers [59]. In clinical practice the total dose dr is given in ν fractions of size dˆr, hence
S(αj , dr) = exp(−ν(αj dˆr + βj dˆ2r)) = exp(−αjdr(1 + dˆr/(αj/βj))).
Concerning chemotherapy, we concentrate on reducing invasion and proliferation and not necessarily
on achieving cell kill. In our model the latter is supposed to be due to ionizing radiation, however
the setting can be easily extended to include a further chemotherapeutic agent 2 triggering cell death.
Most types of cells depend on integrin-mediated adhesion to ECM for migration, proliferation, and
survival. In particular, glioma cells have highly migrating potential, which accounts for glioma re-
currence, often far away from the primary tumor site [15]. Moreover, integrin-ECM interactions have
been shown to increase cell survival after radiation exposure [13]. Supplementary to their role in
cancer cells, integrins on the surface of host cells (e.g., endothelial cells, perivascular cells, fibroblasts
etc.) in the neoplastic microenvironment can boost the malignant potential of a tumor by mediat-
ing angiogenesis, lymphangiogenesis, and desmoplasia [16]. These facts make integrins an attractive
target for anti-tumor therapy, the potential effects being on curtailing angiogenesis, invasion, and
tumor growth, see e.g., [16, 62]. Among the types of integrin inhibitors evaluated in preclinical or
clinical studies, peptidomimetics (RGD3-based small protein-like chains designed to mimic peptides
and blocking ligand binding) are aimed at treating glioblastoma [11]. Examples of pseudomimetics
are cilengitide (targets αvβ3|αvβ6 integrins), ATN 161 (targets α5β1 integrins), and HYD1 (targets
β1 integrins) [11]. In our model we will consider the action of such chemotherapeutic agents.
The effects of chemotherapy are described in our equations by way of dependence on the chemother-
apeutic dose dc. Hence the influences are on the transition rates between proliferating and migrating
phenotypes, on the growth function of the (resting) tumor cells, and on the binding of free receptors
to the tissue fraction surviving irradiation (attachment and detachment rates k+(dc) and k−(dc), re-
spectively, in (4)).
The microscale dynamics of receptor binding is characterized by
y˙ = G(y,Q, dc, dr) = k
+(dc)(1− y)Q S(α3, dr)− k−(dc)y. (4)
In equations (1) and (2) above, the function N denotes the total glioma cell density and is given by
N(t,x) =
∫
V
∫
Y
p(t,x,v, y)dy dv +
∫
Y
r(t,x, y)dy. (5)
2.2 Derivation of the effective equations on the macroscopic level
The model in Subsection 2.1 is a system coupling partial differential equations with an ordinary
differential equation. Its well posedness will be addressed in Subsection 2.3, along with that of the
2The standard treatment for newly diagnosed glioblastoma consists of maximal surgical resection, radiotherapy, and
concomitant and adjuvant chemotherapy with temozolomide, see e.g., [56, 22].
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macroscale equation for N obtained in this subsection via parabolic scaling. Before doing this scaling,
however, we normalize the subcellular dynamics as in [17, 19, 18]. The simplified equation becomes
y˙ = k+(dc)(1− y)QS(α3, dr)− k−(dc)y = −(k+QS + k−)y + k+QS. (6)
The unique steady state of this equation is given by
y∗ =
k+QS
k+QS + k−
= f.
As in [19] we introduce the deviation z := f−y from the steady state and consider the path of a single
cell starting in x0 and moving with velocity v through a time-invariant density field Q(x). Then with
the notation x = x0 + vt it follows that z satisfies the equation
z˙ = f˙ − y˙ = −(k+QS + k−)z + F (t) + f ′(Q)v · ∇Q(x), (7)
where
F (t) := d˙c
(
∂f
∂k+
(k+)′(dc) +
∂f
∂k−
(k−)′(dc)
)
+ d˙rf
′(S)S′(α3, dr).
Thus, choosing (as in [17, 19] the turning rate to be of the form λ(z) = λ0 − λ1z ≥ 0, where λ0 and
λ1 are some positive constants, the transformed system of equations reads:
∂tp+∇ · (vp)− ∂
∂z
(((
k+QS + k−
)
z − F (t)− f ′(Q)v · ∇Q) p)
= −λ0p+ λ0 q(vˆ)
ω
p¯+ λ1zp− λ1z q(vˆ)
ω
p¯− a(x, dc)p+ b(x, dc)q(vˆ)
ω
r − L1(N,α1, dr)p
(8)
∂tr = a(x, dc)p¯− b(x, dc)r + g(N, dc)r − L2(N,α2, dr)r, (9)
where p¯(t,x, y) :=
∫
V
p(v)dv and Li(N,αi, dr) := li(N) +Ri(αi, dr), i = 1, 2.
Now doing the parabolic scaling x→ x, t→ 2t we obtain
2∂tp+ ∇ · (vp)− ∂
∂z
(((
k+QS + k−
)
z − 2F (t)− f ′(Q)v · ∇Q) p)
= −λ0p+ λ0qp¯+ λ1zp− λ1z q
ω
p¯− a(dc)p+ b(dc) q
ω
r − 2L1(N,α1, dr)p (10)
2∂tr = a(dc)p¯− b(dc)r + 2g(N, dc)r − 2L2(N,α2, dr)r. (11)
Thereby, we scaled with 2 the quantity F (t) involving time derivatives of the different doses and the
survival fraction S and accounting for fast dynamics.
In the next step we set up a moment system w.r.t. the involved distribution functions and introduce
the notations
m(t,x,v) =
∫
Z
p(t,x,v, z) dz M(t,x) =
∫
V
m(t,x,v) dv
mz(t,x,v) =
∫
Z
zp(t,x,v, z) dz Mz(t,x) =
∫
V
mz(t,x,v) dv
W (t,x) =
∫
Z
r(t,x, z) dz W z(t,x) =
∫
Z
zr(t,x, z) dz,
where Z ⊆ [y∗ − 1, y∗] is our new domain for the internal dynamics. The higher order moments are
neglected, in virtue of the subcellular dynamics being much faster than the events on the higher scales,
which permits to assume z to be close to zero (i.e., the steady state of the subcellular dynamics is
rapidly reached). As in [17, 19, 18] we assume the functions to have a relatively compact support in
this interval and be compactly supported in the (x,v)-space, which allows to perform the subsequent
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calculations.
With the moment notations we get (after integrating (10) and (11) w.r.t. z):
2∂tm+ v · ∇m = −λ0m+ λ0 q
ω
M + λ1m
z − λ1 q
ω
Mz − a m+ b q
ω
W − 2L1m (12)
2∂tW = a M − b W + 2(g − L2)W (13)
2∂tm
z + v · ∇mz = −(k+QS + k−)mz + f ′(Q)v · ∇Qm+ 2Fm
− λ0mz + λ0 q
ω
Mz − a mz + b q
ω
W z − 2L1mz (14)
2∂tW
z = a Mz − b W z + 2(g − L2)W z, (15)
Now we consider Hilbert expansions Ξ =
∞∑
k=0
Ξk
k, for Ξ ∈ {m,mz,M,Mz,W,W z} and collect corre-
sponding powers of :
0:
0 = −(λ0 + a )m0 + λ0 q
ω
M0 + λ1m
z
0 − λ1
q
ω
Mz0 + b
q
ω
W0
0 = a M0 − b W0
0 = −(k+QS + k− + λ0 + a )mz0 + λ0
q
ω
Mz0 + b
q
ω
W z0
0 = a Mz0 − b W z0 .
From these equations we deduce by integrating w.r.t. v (where appropriate) that Mz0 = 0, W z0 = 0,
mz0 = 0, m0 =
q
ωM0, and W0 =
a
bM0.
1:
v · ∇m0 = −(λ0 + a )m1 + λ0 q
ω
M1 + λ1m
z
1 − λ1
q
ω
Mz1 + b
q
ω
W1 (16)
0 = a M1 − b W1 (17)
v · ∇mz0 = −(k+QS + k− + λ0 + a )mz1 + f ′(Q)v · ∇Qm0 + λ0
q
ω
Mz1 + b
q
ω
W z1 (18)
0 = a Mz1 − b W z1 . (19)
Using the above deduced facts in (19), then in (18) (integrated w.r.t. v) and (16) we obtain Mz1 =
W z1 = 0
mz1 =
1
γ(x)
f ′(Q)v · ∇Q m0 (20)
m1 =
1
λ0 + a
(λ1
γ
f ′(Q)v · ∇Q m0 − v · ∇m0 + aq
ω
M1
)
where γ(x) := k+QS + k− + λ0 + a .
By (16) and (17) we can write
v · ∇m0 = L[λ0 + a]m1 + λ1mz1. (21)
Then L[λ0 +a] defined on the weighted L2-space L2q(V ) with the weight function q−1(vˆ) is a compact
Hilbert-Schmidt operator (see [30]) with pseudoinverse L[λ0 + α]−1|<q>⊥ζ = − 1λ0+αζ. As in [19], this
leads to
m1 = − 1
λ0 + α
(v · ∇m0 − λ1mz1) . (22)
We also have the set of equations
2:
∂tm0 + v · ∇m1 = L[λ0]m2 + λ1mz2 − λ1
q
ω
Mz2 − am2 + b
q
ω
W2 − L1(N0)m0 (23)
∂tW0 = aM2 − bW2 + (g(N0)− L2(N0))W0, (24)
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From (24) we have
b
ω
W2 =
1
ω
[aM2 + (g(N0)− L2(N0))W0 − ∂tW0],
which plugged into (23) leads to
∂tm0 + v · ∇m1 = L[λ0 + a]m2 − L[λ1]mz2 +
q
ω
[a
b
M0(g(N0)− L2(N0))− ∂t(W0)
]
− L1(N0)m0.
After integrating w.r.t. v and rearranging this becomes
∂tM0 +
∫
V
v · ∇m1 dv = (g(N0)− L2(N0))W0 − ∂tW0 − L1(N0)M0.
Hence with N0 = M0 +W0 = (1 + ab )M0 we get
∂tN0 +∇ ·
∫
V
(vm1)dv = (g(N0)− L2(N0))W0 − L1(N0)M0
=
a
a + b
N0(g(N0)− L2(N0))− b
a + b
N0L1(N0). (25)
It remains to express
∫
V
vm1 dv in terms of N0. From (22) we have
m1 = − 1
λ0 + α
(
v · ∇
( q
ω
M0
)
− λ1mz1
)
.
and from (20) we know mz1 =
1
γ(x)f
′(Q)v · ∇Q qωM0, hence
∇·
∫
V
vm1 dv = ∇·
(
− 1
λ0 + a
∇ ·
(
1
ω
∫
V
vvtq dv M0
))
+∇·
(
λ1
λ0 + a
1
γ(x)
f ′(Q)
1
ω
∫
V
vvtq dv ∇QM0
)
.
Now denote
DT (x) :=
1
ω
∫
V
vvtq dv
to obtain
∇ ·
∫
V
vm1 dv = ∇ ·
(
− 1
λ0 + a
∇ · ( b
a+ b
DT (x)N0)
)
+∇ ·
(
λ1
λ0 + a
1
γ(x)
b
a+ b
f ′(Q)DT (x)∇QN0
)
.
Plug this into (25) to obtain the macroscopic equation for N0:
∂tN0 −∇ ·
(
1
λ0 + a
∇ ·
(
b
a+ b
DT (x)N0
))
+∇ ·
(
λ1f
′(Q)
γ(x)
b
(λ0 + a )(b + a )
DT (x)∇QN0
)
=
(
(g(N0)− L2(N0)) a
a + b
− L1(N0) b
a + b
)
N0. (26)
Throughout the rest of this paper we will assume for simplicity that the functions a and b depend
only on time.
2.3 Well posedness of the settings
2.3.1 Micro-meso system
The system (1), (2), (4) fits in the more general framework handled in [41], hence its well posedness
follows (with corresponding initial conditions) like in that reference.
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2.3.2 Macroscopic equation
For the well posedness of the macroscopic equation (26) set in a bounded space-time domain we rely
on the theory of monotone operators for nonlinear parabolic equations (see e.g. [53]).
Let Ω be bounded domain in R3 with Lipschitz boundary ∂Ω. We want to verify the existence of a
solution to the nonlinear parabolic initial-boundary-value problem
∂tu−∇ · (D(x, t)∇u−H(x, t)u) +G(u) = 0 in Ω× (0, T )
(D(x, t)∇u−H(x, t)u) · n = 0 on ∂Ω× (0, T ) (27)
u(0) = u0 on Ω× {0},
where
D(x, t) =
b(t)
(λ0 + a(t) )(a(t) + b(t) )
DT (x)
H(x, t) =
λ1f
′(Q)
γ(t,x)
b(t)
(λ0 + a(t) )(b(t) + a(t) )
DT (x)∇Q− b(t)
(λ0 + a(t) )(a(t) + b(t) )
div(DT (x))
G(u, t) = −
(
(g(u, t)− L2(u, t)) a(t)
a(t) + b(t)
− L1(u, t) b(t)
a(t) + b(t)
)
u.
Assumptions:
(A.i) The functions D and H are continuous in time and essentially bounded in space. Moreover,
D satisfies the condition ξTD(x, t)ξ ≥ θ(t)|ξ|2 with a positive θ(t) bounded away from zero:
0 < cθ ≤ θ(t) ≤ Cθ <∞ for all t ≥ 0.
(A.ii) G is continuous w.r.t. time and the solution variable. Moreover, G satisfies the condition
G(0, t) = 0, the growth condition |G(u, t)| ≤ C(1 + |u|2), with a constant C independent of time
and space, and the coercivity condition inf
ζ∈R+
G(ζ, t)ζ > −∞.
For our concrete setting above we require that:
(i) The diffusion tensor DT is uniformly positive definite and lies in the space W 1,∞(Ω).
(ii) The volume fraction of tissue fibers Q has to lie in the space W 1,∞(Ω), as well.
(iii) The rates a, b, k+ and k− are continuous in the variable dc (which has to be continuous in time),
and uniformly bounded.
(iv) The gain and loss functions g and l (the latter is contained in the expression of Li, i = 1, 2) are
continuous and bounded.
Remark 2.1. Assumptions (i) and (ii) express the fact that the intrinsic properties of the brain
structure are smooth. This can be justified at a reasonable level of detail. Moreover, the diffusion
tensor DT is (re)constructed in such a way that the uniform positive definiteness is assured in every
computational voxel.
Lemma 2.1. For non-negative initial data u0 a solution of (27) remains non-negative for all future
times.
Proof. This follows immediately from our assumptions, by applying the parabolic comparison princi-
ple.
As we are only interested in non-negative initial values, leading to non-negative solutions, we assume
in the following that G(t, u) = 0 for u < 0.
Define the spaces V := H1(Ω) and H := L2(Ω) and the corresponding Gelfand triple (V,H, V ?). We
look for a solution to (27) in the space W := {v ∈ L2(0, T ;V ), v′ ∈ L2(0, T ;V ?)}, with T > 0 fixed.
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Now define the operators
〈A(t)u, v〉 :=
∫
Ω
(D(x, t)∇u−H(x, t)u) · ∇v dx
〈B(t)u, v〉 :=
∫
Ω
G(u, t)v dx
for u, v ∈W .
Remark 2.2. The operators A and B defined above are continuous w.r.t. time, due to (iii).
Lemma 2.2. The family of operators A(t) is continuous from V to V ? and satisfies Garding’s in-
equality
〈A(t)u, u〉 ≥ c1||u||2V − c2||u||2H
with the constants c1 > 0 and c2 ≥ 0.
Proof. The claim follows straightforwardly by usual estimates.
Remark 2.3. We assume without loss of generality that c2 = 0. Otherwise we transform (27) into
an equivalent problem by uˆ = exp(c2t)u. Note that after this transformation the operators A and B
remain continuous in time.
The following result is obtained (as a particular case) by a simple adaptation of the proofs in Section
3.3.6, [53] (or of section III.4, [58]):
Theorem 2.1. Let u0 ∈ H. Under the previous assumptions about the function G and the coefficients
involved in A there exists a solution u ∈W to (27), in the sense that
−
∫ T
0
〈v′(t), u(t)〉V dt+
∫ T
0
〈A(t)u(t), v(t)〉V dt+
∫ T
0
〈B(t)u(t), v(t)〉V = (u0, v(0))H
for all v ∈W with v(T ) = 0. If G is strictly monotone, then the solution u is unique.
3 Assessing the parameters and coefficient functions
3.1 Fiber density q
To determine the diffusion tensor DT we need to determine the fiber orientation distribution q. As is
[17, 19, 18] we could select q to be the peanut distribution proposed by Hillen & Painter in [31]:
q(x,θ) =
n
|Sn−1|tr(DW (x))θ
tDWθ, (28)
where DW denotes the DTI-measured water diffusion tensor and θ ∈ Sn−1 gives the fiber orientation.
The major problem occurring with this choice is that the water diffusion tensor may not reproduce
the brain structure in enough detail, as it consists of only six gradient directions and cannot resolve
crossing fiber tracts [8]. Different other choices try to overcome this drawback. One is to use a bimodal
von Mises-Fisher distribution (see [43]) as proposed in [47]
q(x,θ) =
k(x)
8pi sinh(k(x))
(exp(k(x)φ · θ) + exp(−k(x)φ · θ)), (29)
where k(x) = κFA(x), with the measured fractional anisotropy FA and a real constant κ to be
determined. The vector φ represents the leading eigenvector of the diffusion tensor for each voxel.
This choice, however, has several disadvantages: On the one hand, the parameter κ cannot be measured
and has to be assessed by using different clinical DTI data sets. On the other hand, the fractional
anisotropy is a not satisfactory enough indicator for anisotropy (see [66]), as well as for the fiber density.
Moreover, the leading eigenvector does not resemble the fiber orientation in all voxels [34]. Another
way to enhance the quality of the diffusion tensor description is to use the concept of an orientation
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distribution function (ODF) [8, 1] which describes the probability of diffusion in a direction θ. The
usual definition of this probability is
ODF (θ) =
∞∫
0
P(rθ)r2 dr,
where P(rθ) denotes the displacement probability of a spatial point in spherical coordinates. 4 For
more details we refer to the cited paper. Hence we may set our fiber orientation density to the
orientation distribution function
q(θ) = ODF (θ). (30)
For diffusion tensor imaging the fiber orientation q in (30) can be computed explicitly ([1]):
q(x,θ) =
1
4pi|DW (x)|
(
θtDW (x)−1θ
) 3
2
, (31)
thus we do not need reconstruction procedures involving the integral expression to obtain this quantity.
The ODF is available for different medical imaging techniques [1, 8], among them also the high quality
imaging procedures Q-Ball and HARDI. This is a major advantage allowing to include different medical
data in the model. For our test data 5 we use here this ODF; the issue of comparison between this
and the peanut distribution for the tumor diffusion tensor setup will be addressed in a forthcoming
work.
3.2 Estimation of Q
We estimated the volume fraction of tissue fibers Q as in [18]. Hence we chose
Q = 1− l
3
c
h3
,
where h is the side length of one voxel and the characteristic length lc is estimated via
lc =
√
tr(DW )h2
4l1
,
using l1 as the leading eigenvalue of the diffusion tensor DW . The determination of an unbiased
estimator for the fiber volume fraction is ongoing work.
3.3 Coefficient functions
First we have to select the transition rates a and b between the migrating population p in (1) and
the proliferating population r in (2). These functions depend on the space variable and the dose of
chemotherapeutic agent, however as mentioned before we choose them constant w.r.t. x, as there is no
known procedure to quantify this dependency. As mentioned in Section 2, the chemotherapeutic drug
modeled in this paper concentrates its impact on the integrin bindings. These are essential for cell
migration, thus this has to be taken into account for the choice of a and b. The rate a models the cell
transition from the migrating to the resting (and hence proliferating) regime. As migrating cells seem
to be responsible for the infiltrative behavior of the tumor and its recurrence, we aim at inhibiting
the migratory phenotype of the cell population. Hence, a should be monotonously increasing in its
only variable dc. The rate b describes the transition rate to migratory behavior, so it has to be
monotonically decreasing in dc. Therefore, a possible choice is
a(dc) = 0.05 · (1 + dc)
b(dc) = 0.1 ·
(
1 +
dc
1 + d2c
)
.
4Note that the factor r2 in this expression is often left out, but [1] argued that it is actually essential when considering
normalized solid angles.
5provided by Carsten Wolters, Institute of Biosignal Analysis, WWU Münster, see [64]
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As there is no quantitative information available for these rates, they cannot be fit to measurements.
Therefore, we concentrate on their qualitative behavior. This also applies to the rates k+ and k−.
However, there is some indication that this choice is reasonable, because it is of the same order as the
constants α and β [19] modeling the same rates. The unit of these rates is 1s .
Next we address the receptor binding rates k+ and k−, the first of which describes the rate of a cell
binding to unsoluble ligands (fibers) in its environment, while k− is the detachment rate. Since the
chemotherapeutical agent under consideration is meant to inhibit receptor bindings, we assume the
function k+ to be monotonically decreasing, while k− is supposed to be monotonically increasing.
This means that it is more likely for a cell under the influence of the chemotherapeutical substance
to detach from the ECM than to attach to it. Thus our choices are
k+(dc) = 0.1 ·
(
1 +
dc
1 + d2c
)
k−(dc) = 0.1 · (1 + dc).
This corresponds to the rates selected in [19, 18]. The rate k− could be determined to be around 0.1
in absence of the chemotherapeutical substance [38]. The rate k+ should be larger than k−, since
the attachment of the cell to the surrounding fibers should be more probable then detachment, if no
further (bio)chemical information is available. Like for the rates a and b, the unit of k+ and k− is 1s .
Eventually we have to adjust the functions included in the nonlinear term G and describing radio-
therapy and proliferation. Like in [19, 18], we model the growth in a logistic way and select
g(s) = cg
L1(dc, dr, u) = cgu+
ν∑
i=1
(1− S(α1, dr))ηδ(t− ti)
L2(dc, dr, u) = cgu+
ν∑
i=1
(1− S(α2, dr))ηδ(t− ti).
As in (3), ν is the number of therapy fractions. Altogether we have
−G(w) = a
a+ b
cgw−cgw2−
(
b
a+ b
ν∑
i=1
(1− S(α1, dr))ηδ(t− ti) + a
a+ b
ν∑
i=1
(1− S(α2, dr))ηδ(t− ti)
)
w.
(32)
Note that this G fulfills the requirements of Assumption (A.ii). The growth rate cg has to be mea-
sured in an appropriate way. In [18] we used information about the cell cycle to deduce cg to be
approximately 8 · 10−7 1s − 10−6 1s .
3.4 Constants
We selected the necessary constants as in Table 1 below. The necessary therapy parameters change
from scenario to scenario, so we will specify them where occurring.
4 Numerical simulations
We solve the equation (26). While all necessary data, i.e. the diffusion tensor DT and the volume
fraction of tissue fibers Q, are computed in advance from the DTI measurements using C++ and the
Armadillo linear algebra library [55], we implemented the simulation of the PDE via the numerical
framework DUNE [7, 5, 4, 3]. The coefficients and the drift term depend on time and space, so we
expect time dependent regions of the computational domain that are dominated by the diffusion term
and others dominated by the drift term. Thus we need numerical methods capable to handle both
diffusion dominated and degenerate parabolic equations. Moreover, the selected method has to handle
full tensors and it should be locally mass conservative and positivity preserving.
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Parameter Value Source
s 0.21 · 10−6ms [12]
λ0 0.8
1
s K. Wolf (Radboud Univ. Nijmegen), unpublished data
λ1 10000
1
s estimated, corresponds to [17]
cg ≈ 8 · 10−7 1s − 10−6 1s chosen as in [18].
α1
0.033
Gy − 0.058Gy corresponding to the glioma cell line TK1 in [6]
α2
0.311
Gy − 0.401Gy corresponding to the glioma cell line A172 in [6]
α3
0.37
Gy corresponding to fibroblasts in [6]
β1
0.047
Gy2 − 0.048Gy2 corresponding to the glioma cell line TK1 in [6]
β2
0.061
Gy2 − 0.091Gy2 corresponding to the glioma cell line A172 in [6]
β3
0.016
Gy2 − 0.052Gy2 corresponding to fibroblasts in [6]
Table 1: Model parameters
4.1 Implementation
For the simulations we use a parallel structured quadrilateral mesh as implemented in YaspGrid of
DUNE. The cells are chosen in such a way that we have a subset of the voxel mesh given by the
medical data set consisting of the regions occupied by gray and white matter. These were given by a
segmentation of the brain in the data set. On this mesh we use a cell centered finite volume method
as described in [20]. For the time discretization we employ an implicit Euler scheme with a step size
τ satisfying a CFL-condition near 1. In our case, we considered τ to be one half of a day.
4.2 Results
We performed numerical simulations for different scenarios. The coefficients are those given in Section
3. Different therapy strategies are to be compared, all of which involve resection followed after 21 days
6 by radio- and chemotherapy, the latter applied in a concurrent way. The starting point is considered
the detection of the tumor. Recall that here the chemotherapy is aiming merely at inhibiting receptor
binding to the tissue fibers; the cell kill is achieved by radiotherapy.
Strategy 1: Resection (two weeks after start), no further therapy.
Strategy 2: Resection (two weeks after start), followed after three weeks by radiotherapy
(a daily dose of 2 Gy - except on weekends) for six weeks
Strategy 3: Resection (two weeks after start), followed after three weeks by concurrent
chemotherapy (a normalized dose of 5.0 in our model) and radiotherapy (a
daily dose of 2 Gy - except on weekends) for six weeks.
As therapies with inhibitors of receptor/integrin binding to unsoluble ligands in the environment of
tumor cells are not yet approved for clinical practice, we relied on some clinical trials when designing
the strategies 1 to 4, thereby intentionally omitting the effect of a chemotherapeutic agent (like
temozolomide) directly aiming at cell kill. Hence, these strategies (and the involved parameters)
are motivated by the trials NCT01165333 (Cilengitide in Combination With Irradiation in Children
With Diffuse Intrinsic Pontine Glioma) and NCT00689221 (Cilengitide, Temozolomide, and Radiation
Therapy in Treating Patients With Newly Diagnosed Glioblastoma and Methylated Gene Promoter
Status) at ClinicalTrials.gov.
In our simulations the resection is numerically obtained by depleting all tumor cell densities above a
threshold of 0.2. The maximal chemotherapeutical dose is selected such that the upper value of k− is
of the order chosen in [17, 18, 19].
Figure 1 shows the starting point (when the tumor has been assessed by medical imaging), the time
6For a discussion about the timing of starting radiotherapy after resection see e.g., [36] and the references therein.
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point of resection (two weeks after start), and the result of surgical resection. Observe in Subfigure 1b
the heterogeneous structure of the tumor, which corresponds to the known fact that glioma expand
according to the brain structure, exhibiting a highly anisotropic behavior, as commented in Section
1. Due to this infiltrative growth, the resection is less successful at the tumor margins (Subfigure 1c).
Figure 2 shows the time point at the end of therapy in Strategies 2 and 3 (i.e., nine weeks after
resection), follow-up pictures after two months for the different strategies, and scaled versions of
these pictures. Notice the tumor recurrence which is more pronounced at the marginal region of
the original neoplastic bulk. As expected, resection alone (first column in Figure 2) provides the
poorest therapeutic outcome; the spread of glioma along white matter tracts of the brain tissue leads
to the scattered shape of the tumor. This behavior is in line with clinically observed patterns (see
e.g., [23, 57] and the references therein). Subsequent radiotherapy (middle column in Figure 2) is
expected to enhance tumor eradication, and concurrent chemotherapy aiming at impairing cell-tissue
adhesion by inhibiting receptor binding provides in our simulations an even better outcome (last
column in Figure 2). However, complete eradication seems to be out of reach, as the scaled pictures
in Subfigures 2b, 2d show. This is due to the high proliferation and migration ability of the glioma
cells. We also compared adjuvant and neo-adjuvant chemotherapy (where the same chemotherapeutic
agent was used) with surgery and radiotherapy, but the most significant differences were achieved with
the strategies presented here in more detail. Whenever merely small improvements were obtained we
opted for the less expensive and gentler strategy.
(a) Starting point (b) Before resection (c) After resection
Figure 1: Tumor at starting point, before resection, and after surgical resection.
5 Conclusions and outlook
In this note we started from previous multiscale models for glioma invasion and proposed some descrip-
tions of therapy approaches, partly involving already standard surgery followed by radiotherapy, but
also considering more recent therapeutic ideas connected to inhibition of cell-tissue attachment and its
effects on migration and proliferation. Our multiscale setting with explicit subcellular dynamics seems
particularly well suited to account for such features. Although we eventually work with the effective
equations deduced on the macroscopic level, they carry in their coefficients the information from the
lower (subcellular and individual cell) levels and assimilate DTI data allowing for a patient-specific
description of the brain structure.
Several issues are yet to be addressed in future works; here we mention just a few: (i) When describing
resection we set to zero all densities above 0.2. While this is convenient to do in the computer, in
clinical practice it is hardly possible to zoom (rescale) and assess the tumor heterogeneity at this
level of detail; only the regions with high cell density can be observed by medical imaging and the
tumor volume to be resected/irradiated (i.e., the CTV-PTV margin7) is established by following some
general guidelines. However, our modeling approach opens the way for assessing the evolution of the
tumor on the particular brain structure obtained by DTI and to account thereby for the infiltrative
growth of glioma, which is a main factor in tumor recurrence. Hence, in forthcoming works more
7CTV=clinical target volume, PTV=planning target volume
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(a) End of therapy
(b) End of therapy, scaled
(c) Follow-up after two months
(d) Follow-up after two months, scaled
Figure 2: Comparison of Strategy 1 (left column), Strategy 2 (middle), and Strategy 3 (right).
attention will be paid to tumor delineation and treatment planning. (ii) Throughout the simulations
we used the same DTI-assessed tissue structure via the functions q and Q. Including an equation for
characterizing the evolution of normal tissue would be desirable, but difficult to realize in this frame-
work and with the available data, as the tissue structure would need to be assessed after each stage of
therapy (resection and irradiation), which is expensive (if at all possible, at this level of detail). (iii)
The parameters involved in our simulations have been taken from literature or empirically estimated.
Determining them in a more precise way would mean to combine medical imaging techniques with
biopsy and cell tracking; we refer e.g., to [49] for DTI image-guided biopsy studies. (iv) The effects
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of supplementary cell sensitization towards therapy and even enhancement of tumor cell degradation
can be addressed by considering another chemotherapeutic agent, like temozolomide. It is one of the
great advantages of mathematical modeling to be able to investigate a large variety of therapeutic
approaches and to compare them.
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